What were the key takeaways from Pulse Biosciences’s earnings call?

What is Pulse Biosciences's gross profit margin?

What were the key takeaways from Pulse Biosciences's earnings call?

Did Pulse Biosciences beat or miss consensus estimates last quarter?

What does Pulse Biosciences do and what are its main business segments?

What is the market's earnings forecast for Pulse Biosciences next quarter?

What factors drove the changes in Pulse Biosciences's revenue and profit?

What guidance did Pulse Biosciences's management provide for the next earnings period?

- **Breakthrough Clinical Data**: nPulse catheter achieves 96% 1-year success and 90% arrhythmia freedom, positioning for 2027 CE Mark. Surgical clamp IDE enrollment on track for 2026 completion.
- **Revenue Growth**: Q4 2025 revenue up 207% QoQ to $264K, driven by Vybrance adoption in select accounts.
- **Strategic Focus**: Disciplined commercialization, IP expansion, and $80.7M cash to fund 2026 clinical trials and partnerships.
- **Partnership Potential**: Exploring mapping system integrations to accelerate electrophysiology adoption and procedure efficiency.

**【CEO Summary Section】**
- **Clinical Progress**: Secured IDE approvals for electrophysiology catheter and cardiac surgical clamp programs, with pivotal trial enrollment underway. European feasibility studies show 96% procedural success at 1 year and 90% freedom from atrial arrhythmia for nPulse cardiac catheter. Surgical clamp IDE study expects 136 patient enrollment by end-2026.
- **Commercial Strategy**: Vybrance soft tissue ablation system generated $264K Q4 revenue, up 207% QoQ. Focused on disciplined adoption in key accounts, with PRECISE-BTN study expanding to 100 patients. Collaborating with MD Anderson for thyroid cancer IDE study.
- **IP Strength**: 250 issued patents and 180 pending, including 67 issued in 2025. Differentiated nsPFA technology delivers single-shot ablation in 5 seconds, reducing procedure times by 50%.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Total revenue $264K (up 207% QoQ), GAAP net loss $17.4M, non-GAAP net loss $12.2M. Cash balance $80.7M, supporting 2026 clinical and commercial initiatives.
- **Cash Management**: Q4 cash use $14.8M, driven by clinical trials and commercialization. Filed $200M shelf registration for future liquidity flexibility.

**【Q&A Key Highlights】**
- **nPulse Catheter IDE Enrollment**: Expected to commence in 1-2 months, targeting 155 patients. Improved mapping integration may accelerate enrollment and outcomes.
- **Vybrance Expansion**: Broad commercial release contingent on FDA indication and reimbursement; PRECISE-BTN study on track for 2026 completion.
- **Partnership Strategy**: Exploring collaborations with mapping providers to accelerate nsPFA adoption in electrophysiology.
- **Next-Gen nPulse**: Development underway for integrated regional and focal ablation system, with potential to reduce procedure complexity.
- **Reimbursement Timeline**: Anticipates 4-8 quarters for Vybrance therapeutic clearance, driven by clinical data publication in 2026.

Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript

- **Revenue Milestone**: Generated $86,000 in Q3, marking first commercial sales for Vybrance system.
- **Clinical Momentum**: Over 200 patients treated across thyroid programs; nPulse surgical clamp IDE trial enrolling first patient.
- **Cardiac Device Expansion**: nPulse 360 Catheter IDE submission progressing; European feasibility study shows promising 1-year follow-up data.
- **Financial Position**: $95.2 million cash balance, with Q3 net loss of $19.4 million driven by R&D and commercialization efforts.
- **Strategic Focus**: Scaling Vybrance adoption in select markets while advancing cardiac device trials.

**【CEO Summary Section】**
- **Revenue Generation**: Achieved initial revenue of $86,000 in Q3 2025, driven by Vybrance disposable sales and nPulse capital system placements.
- **Thyroid Ablation Progress**: Over 200 patients treated across pilot programs and PRECISE-BTN study, with physicians reporting high satisfaction and procedural ease. Enrollment in PRECISE-BTN study is 40% complete, targeting 50 patients.
- **Cardiac Device Developments**: 
  - FDA IDE approval for nPulse surgical clamp (NANOCLIP AF) with first patient enrolled; feasibility study in Europe shows ablation times as low as 50 seconds.
  - nPulse 360 Catheter IDE submission progressing; anticipate Q1 2026 trial start. European feasibility study enrolling 150 patients with 1-year follow-up data expected in Q1.
- **Strategic Focus**: Limited market release for Vybrance in select geographies, prioritizing procedure volume and outcome consistency before scaling commercial teams.

**【CFO Financial Commentary】**
- **Financial Performance**: GAAP net loss of $19.4 million (vs. $12.7 million YoY), driven by R&D and commercial expansion. Non-GAAP net loss $13.5 million (vs. $9.4 million YoY). Cash balance $95.2 million, down $11.1 million from Q2 due to operating expenses.
- **Expense Management**: Q3 cash use $13 million, aligned with clinical trial and commercialization investments. Anticipate increased cash use in Q4 with IDE trial enrollment.

**【Q&A Highlights】**
- **nPulse 360 Catheter Trial Funding**: Company plans to self-fund pivotal trial, though open to partnerships for commercialization support.
- **PRECISE-BTN Study Design**: Focuses on composite endpoints including quality of life, symptom reduction, and nodule volume decrease, rather than sole reliance on size reduction.
- **Surgical Clamp Lesion Set**: Surgeon discretion in lesion set based on AF severity; no LAA closure included in trial protocol.


Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript

- **Revenue Momentum**: Initial revenue from thyroid ablation expected in H2 2025, targeting 150,000+ U.S. patients annually.
- **Clinical Breakthroughs**: 40+ successful cardiac clamp procedures in Europe; catheter ablation times reduced to 5-8 minutes.
- **Financial Resilience**: $106.3M cash balance supports clinical trials, with Q2 cash burn of $12.8M.
- **Strategic Partnerships**: Exploring collaborations with EP leaders to accelerate catheter-based ablation commercialization.

**【CEO Summary Section】**
- **Soft Tissue Ablation Progress**: Over 140 patients treated with the percutaneous electrode for benign thyroid nodules, transitioning to ASC/OR settings. A post-market study with 5 sites will begin in Q3, targeting clinical data for FDA submission. Positive outcomes include nodule size reduction and symptom relief without thermal damage.
- **Surgical Ablation Update**: IDE submission for the cardiac clamp under review; 40 patients treated in Europe with rapid, transmural ablations. Feasibility study in the U.S. expected to start soon, with enrollment of up to 150 patients.
- **Catheter-Based AF Ablation**: Over 140 patients treated in Europe with procedure times reduced to 5-8 minutes. IDE submission for the 360 catheter under review; exploring strategic partnerships with EP leaders.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: GAAP net loss of $19.2M (vs. $11.4M in Q2 2024) due to increased administrative and stock-based compensation. Non-GAAP net loss of $13.7M (vs. $9M). Cash balance of $106.3M, with Q2 cash burn of $12.8M.
- **Future Cash Use**: Expect higher R&D spending for IDE trials and commercialization of the percutaneous electrode, with potential revenue recognition in H2 2025.

**【Q&A Highlights】**
- **Thyroid Ablation Market**: Patients prefer non-surgical options due to risks of thyroidectomy. NSPFA's non-thermal, minimally invasive approach addresses unmet needs, with 250,000+ annual U.S. cases.
- **Regulatory Strategy**: IDE submissions for both cardiac devices include European feasibility data. Modular PMA submissions planned to streamline FDA review.
- **Partnerships**: Exploring collaborations with EP leaders for catheter-based ablation, with compatibility demonstrated with Abbott and Johnson & Johnson mapping systems.
- **ASC Potential**: NSPFA's rapid procedure times (45-minute skin-to-skin) and low neuromuscular stimulation make it suitable for ASCs, reducing anesthesia requirements.

Pulse Biosciences (PLSE)-12 Aug 25-2025 Q2 Earnings call transcript

- **Clinical Milestones**: 360 catheter achieves 94.2% pulmonary vein isolation in 22 patients; 100 patients treated in European feasibility studies. Surgical clamp IDE trial expected to begin mid-2025.
- **Commercial Expansion**: Thyroid ablation pilot program treats 90+ patients; commercial launch anticipated in H2 2025 after data collection.
- **Financial Strength**: $119.3 million cash on hand, supported by $14 million warrant exercise proceeds, fueling clinical and commercial growth.

**【CEO Summary Section】**
- **Progress in nsPFA Technology**: Highlighted clinical success with the 360 catheter in treating atrial fibrillation (AF), achieving 94.2% pulmonary vein isolation and 95.5% left atrial posterior wall isolation in 22 patients. European feasibility studies have treated 100 patients, with plans to expand to additional sites in 2025.
- **Commercialization Efforts**: Launched pilot program for the percutaneous electrode in benign thyroid nodule ablation, treating over 90 patients. Aiming for commercial adoption in the second half of 2025 after completing data collection and IRB approvals for a new study.
- **Cardiac Surgical Clamp Development**: Received EU IRB approval to expand feasibility study to 60 patients, with plans to initiate FDA IDE pivotal trial by mid-2025. The clamp is designed for Cox-Maze procedures during open-heart surgery, addressing an unmet need in AF treatment.
- **Financial Update**: Raised $14 million through warrant exercises, maintaining cash position at $119.3 million as of Q1 2025. Focus on advancing clinical trials and commercial infrastructure for soft tissue ablation products.

**【CFO Financial Commentary】**
- **GAAP Results**: Q1 2025 GAAP net loss of $16.8 million, driven by $5.7 million in stock-based compensation and operational expansion costs. Compared to Q1 2024, GAAP costs increased by $7.4 million.
- **Non-GAAP Metrics**: Non-GAAP net loss of $11.4 million, up from $8.1 million in Q1 2024, reflecting higher non-cash expenses. Cash used in operations was $13.5 million, offset by $14.1 million from warrant exercises.
- **Cash Position**: Ended Q1 with $119.3 million in cash, up $1.2 million from year-end 2024, supporting ongoing clinical and commercial activities.

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

- **Breakthrough nsPFA Technology**: Unique nanosecond pulses enable nonthermal, faster ablation with deeper lesions than microsecond PFA.
- **Thyroid Ablation Market Leadership**: 250K annual U.S. patients; pilot data shows 83% nodule reduction at 1 year; commercial launch underway.
- **Cardiac Device Pipeline**: 360 catheter achieves 100% acute success in early trials; surgical clamp IDE planned for mid-2025.
- **Financial Strength**: $118M cash balance; 2025 R&D and commercialization fully funded.

**【CEO Overview】**
- Introduced as the new CEO, emphasizing 45+ years of med tech experience and the potential of nanosecond PFA (nsPFA) technology.
- Highlighted 3 key products: percutaneous electrode for thyroid ablation, cardiac surgical clamp for atrial fibrillation (AF), and 360 catheter for endocardial AF ablation.
- Noted 7 FDA clearances, 6,000+ patients treated, and 180+ issued patents.
- 2025 priorities: commercialize thyroid ablation device, initiate IDE trials for 360 catheter and surgical clamp.

**【CFO Financial Update】**
- Q4 2024 GAAP net loss: $19.4M (vs. $11.9M prior year).
- Non-GAAP net loss: $10.4M (vs. $8.3M prior year).
- Cash balance: $118M (vs. $44.4M prior year), driven by $47.9M from warrant exercises.
- Q4 cash usage: $9.3M (vs. $6.9M prior year).

**【Product Highlights】**
1. **Thyroid Ablation Device**
- 250K annual U.S. patients with benign thyroid nodules; 150K opt for surgery, 100K untreated.
- Pilot program in 8 U.S. centers; Cohort 3 data shows 83% nodule volume reduction at 1 year.
- Commercial launch underway with capital equipment sales and therapy adoption teams.

2. **Cardiac Surgical Clamp**
- 30 patients treated in Europe; preclinical study shows durable, transmural lesions without thermal damage.
- FDA Breakthrough Designation and TAP program engagement; IDE submission planned for mid-2025.

3. **360 Catheter**
- Over 80 patients treated globally; 100% acute lesion success in first 30 patients.
- Unique full circumferential ablation in <5 seconds; no need for cardiac sync or paralytic drugs.
- IDE trial initiation planned for late 2025.

**【Financial Strength】**
- Strong balance sheet ($118M cash) supports clinical trials and commercialization.
- Non-GAAP operating expenses up 29% YoY to $11.3M, driven by R&D and commercial team expansion.


Actual										-0.57	-0.53	-0.51	-0.54	-0.71	-0.58	-0.48	-0.52	-0.58	-0.3744	-0.4561	-0.2209	-0.2266	-0.22	-0.1519	-0.1537	-0.1427	-0.2	-0.1564	-0.1654	-0.17	-0.1988	-0.2028	-0.1829
Forecast										-0.47	-0.5	-0.44	-0.45	-0.495	-0.6933	-0.5333	-0.51	-0.5233	-0.3967	-0.45	-0.24	-0.22	-0.24	-0.24	-0.24	-0.24	-0.24	-0.24	-0.24		-0.26	-0.31	-0.265
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-21.28%	-6.00%	-15.91%	-20.00%	-43.43%	+16.34%	+9.99%	-1.96%	-10.84%	+5.62%	-1.36%	+7.96%	-3.00%	+8.33%	+36.71%	+35.96%	+40.54%	+16.67%	+34.83%	+31.08%	0.00%	+23.54%	+34.58%	+30.98%

Actual	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	574.00K	844.00K	444.00K	265.00K	0	-9.00K	--	--	--	--	--	--	--	--	0	0	86.00K	264.00K
Forecast	--	--	--	--	--	--	--	--	--	0	0	0	0	0	34.13K	188.67K	872.00K	715.33K	439.67K	200.00K	0	0	0	0	0	--	--	--	--	--	0	500.00K	150.00K
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	+204.24%	-3.21%	-37.93%	-39.73%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-82.80%	+76.00%

PLSE

PLSE fundamentals

PLSE Q4 2025 Earnings

Earnings Call

You can ask Aime

PLSE

PLSE fundamentals

PLSE Q4 2025 Earnings

Earnings Call

PLSE Earnings Call Summary for Q4/20254:30 PM on Feb 19, 2026

PLSE Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

PLSE Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

PLSE Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

PLSE Earnings Call Summary for Q4/20244:30 PM on Mar 27, 2025

You can ask Aime